DK3091029T3 - Anti-IL13-antistofformuleringer - Google Patents

Anti-IL13-antistofformuleringer Download PDF

Info

Publication number
DK3091029T3
DK3091029T3 DK16169916.0T DK16169916T DK3091029T3 DK 3091029 T3 DK3091029 T3 DK 3091029T3 DK 16169916 T DK16169916 T DK 16169916T DK 3091029 T3 DK3091029 T3 DK 3091029T3
Authority
DK
Denmark
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
DK16169916.0T
Other languages
English (en)
Inventor
Ajay Deshmukh
Joumana Zeid
Thomas M Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3091029T3 publication Critical patent/DK3091029T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
DK16169916.0T 2011-10-31 2012-10-30 Anti-IL13-antistofformuleringer DK3091029T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553916P 2011-10-31 2011-10-31
EP12846324.7A EP2773662A4 (en) 2011-10-31 2012-10-30 ANTIBODY FORMULATIONS

Publications (1)

Publication Number Publication Date
DK3091029T3 true DK3091029T3 (da) 2023-01-30

Family

ID=48192677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16169916.0T DK3091029T3 (da) 2011-10-31 2012-10-30 Anti-IL13-antistofformuleringer

Country Status (27)

Country Link
US (3) US10000562B2 (da)
EP (3) EP2773662A4 (da)
JP (4) JP6120452B2 (da)
KR (4) KR20190077127A (da)
CN (4) CN104039826A (da)
AR (2) AR088579A1 (da)
AU (3) AU2012332767C1 (da)
BR (1) BR112014008864B1 (da)
CA (2) CA2849210C (da)
DK (1) DK3091029T3 (da)
ES (1) ES2936387T3 (da)
FI (1) FI3091029T3 (da)
HK (1) HK1201857A1 (da)
HR (1) HRP20230153T1 (da)
HU (1) HUE061728T2 (da)
IL (2) IL232053B (da)
LT (1) LT3091029T (da)
MX (2) MX363226B (da)
MY (2) MY187874A (da)
PL (1) PL3091029T3 (da)
PT (1) PT3091029T (da)
RS (1) RS63948B1 (da)
RU (1) RU2665810C2 (da)
SG (1) SG11201401903PA (da)
SI (1) SI3091029T1 (da)
WO (1) WO2013066866A1 (da)
ZA (2) ZA201401779B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2011308496A1 (en) 2010-10-01 2013-05-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
CA2840187C (en) 2011-06-24 2021-01-26 Kci Licensing, Inc. Reduced-pressure dressings employing tissue-fixation elements
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2669395T3 (es) 2011-10-28 2018-05-25 Prothena Biosciences Limited Anticuerpos humanizados que reconocen la alfa-sinucleína
EP2773662A4 (en) 2011-10-31 2015-07-01 Hoffmann La Roche ANTIBODY FORMULATIONS
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
RU2642262C2 (ru) 2012-01-27 2018-01-24 Протена Биосайенсис Лимитед Гуманизированные антитела, которые распознают альфа-синуклеин
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013151669A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
EP3683232A1 (en) * 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015079977A1 (ja) * 2013-11-26 2015-06-04 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
SG11201705019PA (en) 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
UA124269C2 (uk) * 2016-09-23 2021-08-18 Дженентек, Інк. Застосування антагоністу il-13 для лікування атопічного дерматиту
US10980881B2 (en) * 2017-01-11 2021-04-20 Celltrion Inc. Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
EP3701244B1 (en) * 2019-01-02 2023-12-06 Tosoh Corporation Method for determining a radius of gyration of a particle in solution using a light scattering detector
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
EP4065166A4 (en) * 2019-11-26 2023-12-20 Comera Life Sciences, Inc. EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
US20230406920A1 (en) * 2020-10-22 2023-12-21 Allakos Inc. Anti-siglec-8 antibody formulations
EP4370549A1 (en) 2021-07-16 2024-05-22 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis
TW202323291A (zh) 2021-08-13 2023-06-16 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
AU2022345969A1 (en) 2021-09-15 2024-03-07 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
WO2023215769A1 (en) 2022-05-05 2023-11-09 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2876058B2 (ja) 1986-08-18 1999-03-31 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
ATE197398T1 (de) 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
PL184531B1 (pl) 1995-06-07 2002-11-29 Alkermes Inc Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
MXPA04003901A (es) * 2001-11-07 2004-07-08 Cytos Biotechnology Ag Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
MXPA05009135A (es) 2003-02-28 2005-10-20 Ares Trading Sa Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
PT1703893E (pt) 2003-12-23 2012-06-01 Genentech Inc Novos anticorpos anti-il 13 e as respectivas utilizações
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1942939T5 (pl) 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
NZ567124A (en) * 2005-10-21 2011-08-26 Novartis Ag Human antibodies against Interleukin-13 and therapeutic uses to treat asthma
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ES2451540T3 (es) * 2008-12-03 2014-03-27 Astellas Deutschland Gmbh Formas de dosificación oral de bendamustina
EP2403874A1 (en) * 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
SI2550018T1 (sl) * 2010-03-22 2019-05-31 F. Hoffmann-La Roche Ag Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2773662A4 (en) * 2011-10-31 2015-07-01 Hoffmann La Roche ANTIBODY FORMULATIONS

Also Published As

Publication number Publication date
BR112014008864B1 (pt) 2021-11-09
EP3091029B1 (en) 2022-12-28
JP2018048166A (ja) 2018-03-29
CN116077644A (zh) 2023-05-09
HK1201857A1 (en) 2015-09-11
US10000562B2 (en) 2018-06-19
ZA201901490B (en) 2021-06-30
AU2018232943B2 (en) 2020-07-23
CA3078979C (en) 2022-10-11
CN108704132A (zh) 2018-10-26
JP2016193922A (ja) 2016-11-17
US20210155684A1 (en) 2021-05-27
CN104039826A (zh) 2014-09-10
AR124140A2 (es) 2023-02-15
NZ622654A (en) 2017-01-27
IL232053B (en) 2020-08-31
RU2014116070A (ru) 2015-12-10
HUE061728T2 (hu) 2023-08-28
US20140348855A1 (en) 2014-11-27
US20190002552A1 (en) 2019-01-03
HRP20230153T1 (hr) 2023-03-31
JP6272950B2 (ja) 2018-01-31
MX363226B (es) 2019-03-15
ZA201401779B (en) 2019-07-31
EP4218937A2 (en) 2023-08-02
EP4218937A3 (en) 2023-10-25
MX2014004992A (es) 2014-08-27
EP3091029A1 (en) 2016-11-09
CN109078182A (zh) 2018-12-25
JP6921148B2 (ja) 2021-08-18
JP2019203002A (ja) 2019-11-28
AU2018232943A1 (en) 2018-10-11
CN109078182B (zh) 2022-08-12
AU2016210757A1 (en) 2016-08-25
KR20200065104A (ko) 2020-06-08
IL276234B (en) 2022-04-01
IL232053A0 (en) 2014-05-28
KR20170096212A (ko) 2017-08-23
KR20140084078A (ko) 2014-07-04
PT3091029T (pt) 2023-02-03
KR20190077127A (ko) 2019-07-02
SI3091029T1 (sl) 2023-03-31
LT3091029T (lt) 2023-02-27
PL3091029T3 (pl) 2023-04-11
AU2012332767C1 (en) 2017-02-02
ES2936387T3 (es) 2023-03-16
AU2012332767A1 (en) 2014-04-10
EP2773662A4 (en) 2015-07-01
CA2849210A1 (en) 2013-05-10
US10947307B2 (en) 2021-03-16
WO2013066866A1 (en) 2013-05-10
JP2014532664A (ja) 2014-12-08
RS63948B1 (sr) 2023-02-28
BR112014008864A2 (pt) 2018-08-07
EP2773662A1 (en) 2014-09-10
IL276234A (en) 2020-09-30
JP6120452B2 (ja) 2017-04-26
CA3078979A1 (en) 2013-05-10
AU2012332767B2 (en) 2016-05-12
MY197851A (en) 2023-07-20
RU2665810C2 (ru) 2018-09-04
KR102259829B1 (ko) 2021-06-03
KR101994809B1 (ko) 2019-07-01
AR088579A1 (es) 2014-06-18
FI3091029T3 (fi) 2023-03-20
MY187874A (en) 2021-10-26
SG11201401903PA (en) 2014-05-29
CA2849210C (en) 2020-07-14
MX2019002979A (es) 2020-02-10

Similar Documents

Publication Publication Date Title
DK3091029T3 (da) Anti-IL13-antistofformuleringer
DK3117837T3 (da) Antistofformuleringer
DK2694038T3 (da) Farmaceutisk sammensætning
DK3275892T3 (da) Præfusions-rsv-f-antigener
BR112013022112A2 (pt) composição
BR112014002399A2 (pt) conjunto
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
CO6801637A2 (es) Formulaciones de anticuerpos
BR112014004395A2 (pt) composição
CO6940426A2 (es) Formulaciones farmacéuticas
CO6960543A2 (es) 2-tiopirimidinonas
BR112014000015A2 (pt) formulação
BR112013033808A2 (pt) composição
BR112014005756A2 (pt) vacina
DK2690985T3 (da) Møbel
CO6761402A2 (es) Formulaciones inmunosupresoras
BR112014007030A2 (pt) composição
FR2978964B1 (fr) Composition vaccinale anti-il-6
DE112011104936A5 (de) Stanzstauchniet
DK2672817T3 (da) Forbedrede insekticide formuleringer
DE112012000958A5 (de) Handsäge
DE112012000819A5 (de) Gurtbandfänger
BR112013022907A2 (pt) composição farmacêutica
FR2974690B1 (fr) Amplificateur